Avience Biomedicals Limited (NSE:AVIENCE)
India · Delayed Price · Currency is INR 287.40
-2.75 (-0.95%)
At close: Oct 7, 2026
Avience Biomedicals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 525.06 | 452.36 | 239.64 | 109.21 | 101.48 |
Other Revenue | 0.1 | 1.14 | 0 | 0.06 | - |
| 525.16 | 453.5 | 239.64 | 109.26 | 101.48 | |
Revenue Growth | 15.80% | 89.24% | 119.32% | 7.68% | 795.59% |
Cost of Revenue | 289.08 | 271.2 | 156.37 | 77.9 | 75.13 |
Gross Profit | 236.08 | 182.3 | 83.28 | 31.37 | 26.35 |
Selling, General & Admin | 61.67 | 46.19 | 27.36 | 11.68 | 6.65 |
Other Operating Expenses | 23.37 | 16 | 11.55 | 5.38 | 7.52 |
Operating Expenses | 97.26 | 71.01 | 45.08 | 19.15 | 15.14 |
Operating Income | 138.83 | 111.29 | 38.2 | 12.22 | 11.21 |
Interest Expense | -14.33 | -13.13 | -8.76 | -2.37 | -1.47 |
Interest & Investment Income | 0.78 | 0.38 | 0.33 | 0.07 | 0 |
Currency Exchange Gain (Loss) | 0.4 | 0.09 | -0.09 | - | 0.02 |
Other Non Operating Income (Expenses) | -1.07 | -0.38 | -0.32 | -0.33 | -0.14 |
EBT Excluding Unusual Items | 124.61 | 98.25 | 29.35 | 9.59 | 9.62 |
Gain (Loss) on Sale of Assets | 0.04 | -0.14 | 0.07 | - | - |
Other Unusual Items | - | -0.49 | 0.17 | - | - |
Pretax Income | 124.66 | 97.69 | 29.59 | 9.59 | 9.62 |
Income Tax Expense | 37.13 | 26.7 | 8.07 | 1.84 | 2.5 |
Net Income | 87.53 | 70.99 | 21.52 | 7.76 | 7.13 |
Net Income to Common | 87.53 | 70.99 | 21.52 | 7.76 | 7.13 |
Net Income Growth | 23.30% | 229.94% | 177.37% | 8.86% | 1394.08% |
Shares Outstanding (Basic) | 4 | 4 | 3 | 3 | 1 |
Shares Outstanding (Diluted) | 4 | 4 | 3 | 3 | 1 |
Shares Change | 6.26% | 15.51% | 23.04% | 98.43% | 2046.71% |
EPS (Basic) | 21.71 | 18.71 | 6.55 | 2.91 | 5.30 |
EPS (Diluted) | 21.71 | 18.71 | 6.55 | 2.91 | 5.30 |
EPS Growth | 16.04% | 185.67% | 125.41% | -45.14% | -30.40% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -75.42 | -59.04 | -28.96 | -1.01 | -28.31 |
Free Cash Flow Per Share | -18.71 | -15.56 | -8.82 | -0.38 | -21.05 |
Gross Margin | 44.95% | 40.20% | 34.75% | 28.71% | 25.97% |
Operating Margin | 26.43% | 24.54% | 15.94% | 11.18% | 11.05% |
Profit Margin | 16.67% | 15.65% | 8.98% | 7.10% | 7.02% |
Free Cash Flow Margin | -14.36% | -13.02% | -12.08% | -0.92% | -27.90% |
EBITDA | 150.86 | 119.93 | 44.36 | 14.31 | 12.18 |
EBITDA Margin | 28.73% | 26.45% | 18.51% | 13.10% | 12.00% |
D&A For EBITDA | 12.04 | 8.64 | 6.17 | 2.09 | 0.97 |
EBIT | 138.83 | 111.29 | 38.2 | 12.22 | 11.21 |
EBIT Margin | 26.43% | 24.54% | 15.94% | 11.18% | 11.05% |
Effective Tax Rate | 29.79% | 27.33% | 27.28% | 19.13% | 25.94% |
Revenue as Reported | 527.95 | 459.08 | 243.73 | 109.34 | 101.49 |
Advertising Expenses | 11.71 | 10.13 | 4.09 | 2.66 | 0.08 |